
Benefits of a National Patient Registry
Also Available In: Japanese Patient registries are crucial for monitoring trends in health, allocating resources, organizing and tracking distribution of
Year: 2016
Language: Polish
Author(s): World Federation of Hemophilia
Format: Document
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese
This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for the translation or for any errors or changes to content from the original English edition. Patient organizations interested in translating a WFH resource must first obtain permission from the WFH, available here.
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

Also Available In: Japanese Patient registries are crucial for monitoring trends in health, allocating resources, organizing and tracking distribution of

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia

Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese 患者登録は、健康上の傾向のモニタリング、資源の割り当て、治療用製剤供給の調整および追跡、全国規模での購入プロセスの改善に極めて重要です。

Also Available In: Japanese Access to home treatment reduces the economic impact on healthcare systems and improves the quality of

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia

Highlights the various options available when treatment products are extremely scarce. Even with a limited amount of coagulation factor, it